Navigation Links
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
Date:6/13/2013

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ --

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation  at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia.

ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations.

Details on the Presentations are as follows:

Title: Constant Therapeutic Levodopa Plasma Concentrations Maintained by Continuous Subcutaneous Administration of ND−0612, a Novel Formulation of Levodopa/Carbidopa
Abstract #: 452
Presenter: Peter LeWitt
Poster session: Parkinson's Disease: Clinical Trials
Date and time: Tuesday, June 18th, 12:30pm
Location: Bayside, level, 1 gallery B

Title: ND0612, A Novel Formulation of Levodopa/Carbidopa for Continuous, Subcutaneous Administration, Achieves Steady-State Levodopa Plasma Concentrations in Parkinson's Disease Patients
Abstract #: LBA26
Presenter: Nir Giladi
Poster session: Late Breaking Abstracts
Date and time: Wednesday, June 19th, 12:00pm
Location: Exhibit hall #5

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well-established oral drugs that achieve better efficacy. The company's lead products are ND0612, a novel sub-cutaneous drug formulation for the treatment of Par
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
2. NeuroDerm to Present at the Jefferies 2013 Global Healthcare Conference in New York City
3. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
4. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
5. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
8. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
9. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
10. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
11. Mindray Announces Appointment of Three Members to Its Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... (Nasdaq: ERES ), a global provider of ... device industries, today announced that Michael McKelvey will be ... Officer and a director of ERT.  The Company,s Board ...  Dr. McKelvey will continue in his current position until ...
... Sept. 10 Covance Inc. (NYSE: CVD ) ... Global Healthcare Conference on Tuesday, September 14, 2010 at 2:10 ... presentation at www.covance.com .  In order to register and ... Covance, with headquarters in Princeton, New Jersey, is ...
Cached Medicine Technology:ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 2ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 3
(Date:7/25/2014)... Progress in understanding the molecular genetics of brain ... brain tumor treatments, according to Patrick Wen, MD, professor ... for Neuro-Oncology, Dana-Farber Cancer Institute. , At the American ... in Chicago, July 25-26, Dr. Wen will moderate a ... the development of new treatments and advancing strategies to ...
(Date:7/25/2014)... San Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and ... MaaS360 Market, and will leverage the MaaS360 WorkPlace ... corporate data. , Splashtop Business and Splashtop Enterprise offer ... using any device. High performance, ease of ...
(Date:7/25/2014)... July 25, 2014 Garth Brooks Chicago ... the Allstate Arena in Rosemont. Garth Brooks was one of ... released his first single in 1989. Since "Much Too Young (To ... the shows from the Tulsa, Okl. native and in the years ... see him back on a stage and in the recording studio. ...
(Date:7/25/2014)... be treated more quickly after Manchester research , ... blood test on arrival, is effective in reducing ... study shows., The findings of a research group ... could potentially make a huge difference to a ... most common reason for emergency hospital admission. In ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Ross A. ... has been invited to join the exclusive Obagi Clinical ... leading facial plastic surgeons, plastic surgeons and dermatologists. ... this exclusive Advisory Board of thought leaders held its ... the meeting was to give Obagi the opportunity to ...
Breaking Medicine News(10 mins):Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2
... $1.1 million grant to a team of scientists at the ... technology for studying the link between human health and disease ... body. The grant is one of 14 awarded nationwide ... the Human Microbiome Project. The human microbiome consists of beneficial ...
... HealthDay Reporter , TUESDAY, Sept. 14 (HealthDay News) -- ... accurate decisions in all aspects of life, new findings suggest. ... the journal Current Biology theorize that action games ... drawn from their senses in decision-making, a skill known as ...
... , TUESDAY, Sept. 14 (HealthDay News) -- Nearly half ... payments from companies that make orthopedic devices such as artificial ... articles on such devices in medical journals, a new study ... who read the articles aren,t aware of conflicts of interest ...
... Researchers at Children,s Hospital Boston have developed a ... North Carolina at Chapel Hill to engage health care ... safety and real-time pharmacovigilance. The application, "MedWatcher," allows users ... official alerts from the Food and Drug Administration (FDA), ...
... today (14 September 2010), shows that the watercress compound is ... plays a critical role in cancer development. As tumours ... send out signals which make surrounding normal tissues grow new ... nutrients. The research, led by Professor Graham Packham ...
... ROCKVILLE, Maryland, September 14, 2010 Neuralstem, Inc. ... stem cells survived in rat brains affected by ... animals showed significant improvement in some motor skill ... of Adherent Human Neural Stem Cells To Reverse ...
Cached Medicine News:Health News:New research technology to target human gut bacteria 2Health News:Action-Packed Video Games May Be Good for You After All 2Health News:Action-Packed Video Games May Be Good for You After All 3Health News:Medical Study Authors Often Fail to Disclose Industry Ties 2Health News:New iPhone app, 'MedWatcher,' to support real-time drug safety surveillance 2Health News:Watercress may 'turn off' breast cancer signal 2Health News:Neuralstem stem cells survive and differentiate into neurons in rats with stroke 2
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
Medicine Products: